Stocks › Biotechnology › FTH

Faeth Therapeutics FTH

US equityMarket cap rank #3571Biotechnology

$24.92 −$1.97 (-7.33%)

Market closed · Oct 8, 7:00 am ET · Last extended-hours $24.92 0.00%

Open$26.71

Prev close$26.89

Day range$23.95 – $27.03

Volume322.6K

Market cap$643.94M

P/E (TTM)–

Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership66.0%-0.02 pts vs. prior quarter

Institutions holding51+0 vs. prior quarter

Insider trades (recent)24 buys / 16 sellsNet buying

Short interest5.10% of floatDays to cover 4.4 · as of 15 Sep 2026

Short-sale volume share21.0%5-day average of daily volume

Short-sale volume as % of daily volume

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: +$1.27M (9 inflow days, 11 outflow days).

Net flow by order size, last 20 sessions

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 32.6% of shares outstanding.

Largest holders

Khosla Ventures, LLC10.19%
Montanova Capital, LLC7.82%
Avoro Capital Advisors LLC5.59%
Baker Bros. Advisors LP4.98%
Balyasny Asset Management L.P.4.03%
Cormorant Asset Management, LP3.98%
Anand Parikh3.16%
RA Capital Management, L.P.2.79%

By investor type

Hedge Fund45.40%
VC/PE Fund17.42%
Individual/Insider4.27%
Mutual Fund2.15%
Private Company0.67%
Family Office/Trust0.31%
Public Company0.07%

Reported short interest has risen from 3.03% to 5.10% of float over the last 6 biweekly reports (30 Jun 2026 to 15 Sep 2026).

Recent institutional activity

Holder	Type	Period	Share change	New stake
Montanova Capital, LLC	Hedge Fund	2026/Q3	+1,985,554	7.8%
Avoro Capital Advisors LLC	Hedge Fund	2026/Q3	+1,444,039	5.6%
Baker Bros. Advisors LP	Hedge Fund	2026/Q3	+1,286,411	5.0%
Balyasny Asset Management L.P.	Hedge Fund	2026/Q3	+1,025,993	4.0%
Cormorant Asset Management, LP	Hedge Fund	2026/Q3	+722,020	4.0%
Fairmount Funds Management LLC	Hedge Fund	2026/Q3	+722,020	2.8%
RA Capital Management, L.P.	VC/PE Fund	2026/Q3	+722,020	2.8%
Logos Global Management, L.P.	Hedge Fund	2026/Q3	+692,020	2.8%
The B Group, Inc.	Hedge Fund	2026/Q3	+610,169	2.4%
Caligan Partners, LP	Hedge Fund	2026/Q3	+503,465	2.4%
Trails Edge Capital Partners, LP	Hedge Fund	2026/Q3	+390,335	2.0%
ADAR1 Capital Management, LLC	Hedge Fund	2026/Q3	+361,010	1.4%
Franklin Resources	Mutual Fund	2026/Q3	+361,010	1.9%
Octagon Capital Advisors LP	Hedge Fund	2026/Q3	+361,010	1.4%
Boxer Capital Management, LLC	Hedge Fund	2026/Q3	+180,505	0.7%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

Date	Insider	Title	Transaction	Shares	Price	Held after
10 Sep 2026	Karen Vousden	Scientific Co-Founder	Other Derivative Acquisition	+25,000	$37.44	25,000
10 Sep 2026	Karen Vousden	Scientific Co-Founder	Initial Statement of Beneficial	+0	–	42,631
21 Jul 2026	Cambrian BioPharma, Inc.		Intent to Sell (Form 144)	-130,142	$27.99	–
20 Jul 2026	Anand Parikh	Chief Operating Officer	Other Derivative Acquisition	+398,018	$28.37	398,018
20 Jul 2026	Josiah Craver	Officer	Other Derivative Acquisition	+30,824	$28.37	30,824
30 Jun 2026	Brian Stephenson	Chief Financial Officer	Open Market Acquisition	+13,634	$24.98	46,688
25 Jun 2026	Brian Stephenson	Chief Financial Officer	Open Market Acquisition	+15,641	$27.77	33,054
22 Jun 2026	Brian Stephenson	Chief Financial Officer	Open Market Acquisition	+17,413	$25.91	17,413
21 Jun 2026	Anand Parikh	Chief Operating Officer	Open Market Acquisition	+2,806	$19.76	817,699
21 Jun 2026	Anand Parikh	Chief Operating Officer	Derivative Exercise and Retained	+53,465	$1.16	817,699
14 Jun 2026	Khosla Ventures, LLC		Initial Statement of Beneficial	+0	–	2,632,232
14 Jun 2026	Stephen Hahn	Director	Derivative Exercise and Retained	+44,763	–	44,763
14 Jun 2026	Anand Parikh	Chief Operating Officer	Derivative Exercise and Retained	+761,428	–	761,428
12 Jun 2026	Brian Stephenson	Chief Financial Officer	Initial Statement of Beneficial	+0	–	166,435
11 Jun 2026	Sona Saira Ramasastry	Director	Other Derivative Acquisition	+25,000	$13.00	25,000
11 Jun 2026	Sona Saira Ramasastry	Director	Initial Statement of Beneficial	+0	–	14,647
11 Jun 2026	Stephen Hahn	Director	Other Derivative Acquisition	+25,000	$13.00	25,000
11 Jun 2026	Stephen Hahn	Director	Initial Statement of Beneficial	+0	–	44,763
9 Jun 2026	Robert Holmen	Independent Director	Other Derivative Acquisition	+12,500	$11.41	12,500
9 Jun 2026	Phillip Donenberg	Director	Other Derivative Acquisition	+12,500	$11.41	12,500

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report date	Shares short	% of float	Days to cover
15 Sep 2026	1,318,893	5.1%	4.4
31 Aug 2026	1,098,324	4.3%	3.7
14 Aug 2026	827,167	3.2%	2.8
31 Jul 2026	815,587	3.2%	2.8
15 Jul 2026	890,306	3.5%	3.8
30 Jun 2026	780,396	3.0%	7.0

Discussion

No comments yet — be the first to weigh in on FTH.